The emblem for the Meals and Drug Administration is seen forward of a information convention on the Well being and Human Providers Headquarters in Washington, DC on April 22, 2025.
Nathan Posner | Anadolu | Getty Photos
A key U.S. Meals and Drug Administration official who oversees vaccines and biotech therapies will step down from the company following a number of selections that raised issues throughout the business.
Vinay Prasad, director of the Middle for Biologics Analysis and Analysis, will go away the FDA on the finish of April, an company spokesperson confirmed on Friday.
In a put up on X, FDA Commissioner Marty Makary stated the FDA will appoint a successor earlier than Prasad returns subsequent month to the College of California San Francisco, the place he taught earlier than taking the FDA place final 12 months. Makary stated Prasad “received an amazing quantity achieved” throughout his tenure on the company.
Prasad’s determination to step down comes after criticism of the FDA mounted throughout the biotech and pharmaceutical business and amongst former well being officers. Prior to now 12 months, the company has denied or discouraged the approval functions of a minimum of eight medication, in response to RTW Investments, after taking situation with knowledge the businesses used to assist their functions. The FDA additionally refused to overview Moderna’s flu shot earlier than it reversed course.
All of these firms accused the FDA of reversing earlier steerage concerning the proof they may use to again their functions, sparking criticism throughout the business that an unreliable regulatory course of might stifle growth of medicine for hard-to-treat illnesses.
A former FDA official who spoke to CNBC on the situation of anonymity to talk freely on the problem referred to as the reversals the worst type of regulatory uncertainty as a result of firms say they’re being advised one factor after which expertise one other.
In an announcement earlier Friday, an FDA spokesperson stated there was “no regulatory uncertainty,” including the company “makes selections based mostly on the proof, however doesn’t make assurances about outcomes.” The spokesperson stated the FDA is “conducting rigorous, impartial evaluations and never rubber-stamping approvals.”
The newest controversy got here after the FDA discouraged UniQure from making use of for expedited approval of its experimental therapy for Huntington’s illness.
The company, which underwent workers cuts and an overhaul beneath Well being and Human Providers Secretary Robert F. Kennedy Jr., has confronted broader backlash for its drug and vaccine approvals course of. Critics have fearful the company might stifle the event of recent therapies and threat the security of sufferers.
The Wall Avenue Journal earlier reported Prasad’s departure.
